Brief: Travere Therapeutics Q3 EPS USD 0.28
30/10/2025 20:01
Oct 30 (Reuters) - Travere Therapeutics Q3 operating income USD 24.931 million. Q3 operating expenses USD 139.928 million Q3 product sales USD 113.15 million Q3 net income USD 25.706 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule